The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial
-
Published:2024-08
Issue:
Volume:597
Page:217041
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Lim Sung Hee,
Saluja Ashok,
Vickers SelwynORCID,
Hong Jung YongORCID,
Kim Seung Tae,
Lavania Shweta,
Pandey SomnathORCID,
Gupta Vineet K.,
Velagapudi Mohana R.,
Lee Jeeyun
Reference22 articles.
1. Prediction of cancer incidence and mortality in Korea, 2022;Jung;Cancer research and treatment,2022
2. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet (London, England),2021
3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial;Rha;Lancet Oncol.,2023
4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol.,2014
5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial;Shitara;Lancet Oncol.,2018